NEA Management Company’s Gyre Therapeutics GYRE Stock Holding History

NEA Management Company’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,799	Closed	-$220K	–	45
2017 Q3	$220K	Hold	5,799	–	–	0.01%	44
2017 Q2	$202K	Hold	5,799	–	–	0.01%	44
2017 Q1	$410K	Hold	5,799	–	–	0.01%	37
2016 Q4	$424K	Hold	5,799	–	–	0.02%	39
2016 Q3	$789K	Hold	5,799	–	–	0.04%	39
2016 Q2	$992K	Hold	5,799	–	–	0.05%	38
2016 Q1	$1.1M	Hold	5,799	–	–	0.07%	36
2015 Q4	$2.04M	Hold	5,799	–	–	0.13%	31
2015 Q3	$3.04M	Hold	5,799	–	–	0.2%	32
2015 Q2	$12.7M	Hold	5,799	–	–	0.67%	23
2015 Q1	$13.6M	Hold	5,799	–	–	0.61%	24
2014 Q4	$12M	Hold	5,799	–	–	0.58%	26
2014 Q3	$11.6M	Hold	5,799	–	–	0.59%	27
2014 Q2	$20.6M	Hold	5,799	–	–	0.97%	19
2014 Q1	$21.7M	Hold	5,799	–	–	1.06%	17
2013 Q4	$19M	Sell	5,799 -8	-0.1%	-$31.5K	0.92%	18
2013 Q3	$24.3M	Hold	5,807	–	–	0.96%	16
2013 Q2	$19.5M	Buy	+5,807	New	+$22.1M	0.87%	17

Other funds holding GYRE

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NEA Management Company's GYRE Position: Q4 2017 in Review

NEA Management Company sold out of Gyre Therapeutics (GYRE) in Q4 2017, closing a stake of 5,799 shares — an estimated $220K sold.

NEA Management Company first reported a position in GYRE in Q2 2013 and held it in 18 quarters. The position peaked at $24.3M in Q3 2013. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2017.

NEA Management Company reported no remaining Gyre Therapeutics position as of Q4 2017 after selling out during the quarter.
NEA Management Company sold 5,799 Gyre Therapeutics shares in Q4 2017, an estimated $220K.
NEA Management Company first reported a position in Gyre Therapeutics in Q2 2013 and held it in 18 quarters.
NEA Management Company's Gyre Therapeutics position peaked at $24.3M in Q3 2013.
35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2017.

Based on NEA Management Company's 13F filing for Q4 2017, filed 8 Feb 2018.